Publication | Closed Access

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

Diabetes ManagementCardiovascular DiseaseMedicineDiabetesSustain 2Clinical TrialsType 2PharmacotherapyDiabetes MellitusPhase 3APharmacologyAnticoagulant